Novartis and Johnson & Johnson to deprive Europeans of their right to Health

Novartis-Logo (1)

It was the last day of January that the European Commission decided to send a formal complaint against two pharmaceutical giants, Johnson and Johnson and Novartis, over an illegal secret deal that made European cancer patients suffer while it brought huge profits to the American and Swiss multinational accordingly.

After the meticulous research of DG Competition, that as usually, took around 10 years to bear fruit, it has been uncovered that the two of the three biggest Pharmaceutical companies of the world according to Forbes, were having a small party in Netherlands between 2005 and 2006 at the expense of the Dutch cancer patient. According to DG Comp, what was happening back then is that the Dutch branch of Johnson & Johnson in the Netherlands, Janssen-Cilag, had in its payroll for one year and a half a competitive pharmaceutical company specialized in generics called Sandoz. The latter is a proper known unit of the Swiss company Novartis. So, basically, Johnson and Johnson were paying to Novartis a huge amount of money for 17 months. Isn’t that weird? Competitor companies are supposed to have endless board meetings on how to steal money from each other and not sharing bribes. Was 2005 the year that the management of the two powerful companies lost their minds due to burnout?

The Pay for Delay Deal

Well, think again! These people knew very well what they were doing. We are talking here about the anticompetitive bad practice of Pharmaceuticals called “Pay for Delay” where one brand name is bribing the generic drug competitor in order to delay the release of the cheaper generic drug in the market. In our case the generic drug that was deliberately and illegally delayed to launch in the Dutch market is Fentanyl and it is a drug that is mainly used by cancer patients to relieve pain. In a nutshell, these two companies deprived the Dutch cancer patients from the right to be able to buy a much cheaper drug, so that they can save millions of Euros by preventing a market share loss that a cheaper substitute product in the market would bring.

On the antitrust statement of DG Competition on the 31st of January, Mr. Almunia, the EU Competition Commissioner, said: “If our preliminary conclusions are confirmed, the Dutch subsidiaries of Johnson & Johnson and Novartis entered into a so-called “co-promotion” agreement to avoid competing against each other, depriving users of fentanyl in the Netherlands from access to a cheaper pain killer,”… “The commission is determined to fight undue delays in the market entry of generic medicines so that European citizens have access to affordable health care”. The Basque EU Commissioner says it here very well, but he certainly cannot say anything to the Dutch patients that were not given the alternative of cheap Fentanyl for 17 monhts! Can he?

DG Comp is doing Fundraising

Unfortunately, it seems that this antitrust statement can serve only in two things: a) make impression and b) make the Commission richer. If the Commission wins this battle with the pharmaceutical dinosaurs, which we all hope it will, the only benefit will be a few billion Euros for DG Comp. And of course we live in crisis and Mr. Almunia needs to play the role of the Fundraiser but in the end of the day this will not solve the Pay for Delay syndrome that is expanding like a plague in Europe and is menacing significantly public health. I mean, what is 7 billion euros for Johnson and Johnson to pay as fine compared to the millions or billions that the company has probably saved by exercising this anticompetitive covert technique? And of course, we are talking here about one case that goes back 10 years ago and was uncovered now. Who knows how many other similar incidents we had or we have at this moment in Europe happening at the expense of the European citizen, which will never see the light of publicity? Hence, the culminant question here is: What next? How can the European citizen be sure that this kind of corporate bribing will not be repeated in the future?

The European Parliament had an idea

Only a week after the antitrust statement, a new draft law was voted on the 6th of February in the European Parliament that seems relevant to the topic of this story. The basic concept behind that is that European patients should be able to buy cheaper generic medicines. This is an excellent concept. The European Sting and all Europeans welcome this spirit from the European law makers without a doubt. However, the European Parliament only voted in favour of some new deadlines and transparency standards on pricing and reimbursement of generic medicines. As usually, all this will be addressed to the 27 member states.

Of course, this is something that Europe needed to have anyway, because the rules that are now in action and describe these procedures are almost 25 years old (1989). It is true that the procedures were poorly defined and slow while, as Mrs. Antoniya Parvanova, rapporteur from the Alliance of Liberals and Democrats for Europe (ALDE), said, sometimes it took a country up to 700 days to make decisions on pricing and reimbursement of medicines. However, why was this matter brought up in the European Parliament now and not before? Is it to take the next step after Mr. Almunia’s antitrust statement?

I am afraid not. The reasons are twofold:

a)      This vote apparently is not going to stop Pharmaceuticals to pay for delay

b)      The draft law was voted on the 6th of February, when on the 4th was the World Cancer Day. The period that the draft law was voted was a period with numerous events aiming at cancer awareness all around the world. Is it a coincidence that the flash addicted European Parliament voted for this in the beginning of February and not in March?

Overall the draft law is a good reform addressed to member states to improve the European health system as a whole but let’s be honest here. Big Pharmaceuticals will be still free out there to sign golden deals under the table with generic competitors, in order to delay the launch of their product so that they keep the prices and profits high for themselves. Who will touch these people? Or better who can touch these people? Is a few billion fine enough to make them stop?

I guess not. The only cure from this cancer is that the patient, the European citizen, is aware of what exactly is happening behind her back and I hope that with this story the Sting has contributed to that.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Syria’s groundbreaking constitutional talks: ‘a clear success of mediation’ says Guterres in Turkey

10 million Yemenis ‘one step away from famine’, UN food relief agency calls for ‘unhindered access’ to frontline regions

“911, What’s your emergency?”

Nearly a third of the globe is now on Facebook – chart of the day

Climate change is forcing 20 million people a year from their homes, Oxfam says

4 ways Africa can prepare its youth for the digital economy

Germany objects to EU Commission’s plan for a Eurozone bank deposits insurance scheme but Berlin could go along

Alcohol abuse kills three million people a year, most of them men – WHO report

2013, a Political Odyssey: What future for Italy?

This is why mental health should be a political priority

Commission welcomes European Parliament adoption of EU4Health programme

Commission welcomes agreement on the modernisation of EU export controls

7 ways to break the fast fashion habit – and save the planet

ECB again to subsidize euro area banks with more than one trillion euro

Thomas Cook bankruptcy: Better consumer and employee protection needed

MWC 2016 LIVE: Ingenu steps up efforts to build LPWA networks across the globe

Greener tourism: Greater collaboration needed to tackle rising emissions

How digital entrepreneurs will help shape the world after the COVID-19 pandemic

MEPs back plans to promote water reuse for agricultural irrigation

The ECB proposes a swift solution for SMEs’ financing

Working fewer hours makes you more efficient. Here’s the proof

COVID-19: A coordinated EU health strategy needed, say MEPs

‘BioSolar Leaves’ are better at cleaning the air than trees, say the technology’s developers

EU leaders agree to delay Brexit until 31 October

Yemen war ‘a test of our humanity’, and we’re ‘badly failing’ warns UN Children’s Fund chief

German Presidency outlines priorities to EP committees

The refugee crisis seen through the eyes of a young doctor from Turkey

EU, Latin America and the Caribbean: Partnering for prosperity, democracy, resilience and global governance

Collective action to enable sustainable growth will be critical to end tropical deforestation

Adoption of new rules to better protect children caught in cross-border parental disputes

Arrest of three Libyans wanted for grave crimes ‘would send strong and necessary message’ to victims, urges top Prosecutor

State aid: Commission approves around €36 million Romanian rescue aid to state-owned flag carrier TAROM

COVID-19: from the chaos of the pandemic to the difficulties in vaccination

Ecofin: ‘The Friday battle’ for the banking union

Haiti cholera outbreak ‘stopped in its tracks’

The UK option: An overarching alternative for the whole Brexit options

Security Council gravely concerned by Ebola outbreak in DR Congo, demands immediate end to violence hampering response

Here’s how to achieve growth in the Middle East and North Africa

Civil society groups matter for Cambodia’s sustainable development: UN expert

European Institute of Innovation and Technology: Commission welcomes political agreement on strategy for 2021-2027

The von der Leyen Commission: for a Union that strives for more

Number of MEPs to be reduced after EU elections in 2019

The challenge of palliative care in universal health coverage

The world needs carbon-neutral flying. Here’s how to bring it one step closer

Facts, not fear, will stop COVID-19 – so how should we talk about it?

Concorde is a reminder that the only way for innovation is up

Parlamentarians to “break up” with reality in the Google antitrust case

Implementation of tax transparency initiative delivering concrete and impressive results

The world has made spectacular progress in every measure of well-being. So why does almost no one know about it?

EU guidance on the handling of visa applications from residents of Ukraine’s Donetsk and Luhansk regions

MEPs to prioritise environment and climate action in next long-term budget

GDP growth slows in most G20 economies in third quarter of 2019

This is why retail is such a sore point in India-US trade relations

Khashoggi murder trials must public and meet international standards, UN expert urges

UN chief seeking ‘renewed commitment’ to global rules and values, as world leaders head to New York

Agriculture and Fisheries Council

A reality check on inclusive innovation

Austerity lovers to put a break on Renzi’s growth vision for Europe? the Sting reports live from World Economic Forum 2015 in Davos

This man is turning cities into giant sponges to save lives

4 key trends on how COVID has impacted women in business

More Stings?

Comments

  1. I believe this is one of the so much important information for me.
    And i’m satisfied studying your article. But wanna
    remark on few basic things, The site style is perfect, the articles is in point of fact excellent : D.
    Just right task, cheers

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s